Evidence map›Paper›PMID 28358926›Full record

ArticlePloS one2017

Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer.

Nina P Connolly, Jesse A Stokum, Craig S Schneider, Tatsuya Ozawa, Su Xu, Rebeca Galisteo, Rudolph J Castellani, Anthony J Kim, J Marc Simard, Jeffrey A Winkles and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Enhanced Glioblastoma Detection ThroughMagnetic resonance in medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Rat and Mouse Brain Tumor Models for Experimental Neuro-Oncology Research.Journal of neuropathology and experimental neurology · 2022
    Review
  6. Article
  7. Review
  8. Pre-clinical tumor models of primary brain tumors: Challenges and opportunities.Biochimica et biophysica acta. Reviews on cancer · 2021
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Nina P ConnollyDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.ORCID http://orcid.org/0000-0003-0498-6148
Jesse A StokumDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Craig S SchneiderDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Tatsuya OzawaFred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States of America.
Su XuDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Rebeca GalisteoDepartment of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Rudolph J CastellaniDepartment of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Anthony J KimDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
J Marc SimardDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Jeffrey A WinklesMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Eric C HollandFred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States of America.
Graeme F WoodworthDepartment of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
University of Maryland, Baltimore · USUniversity of Washington · US

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Transitioning Early Career Neurosurgeons to Scientific IndependenceK12NS080223 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI ESKANDAR, EMAD N · 2012 to 2022
$9.2M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Brain-Penetrating Nanoparticle Therapeutics for Invasive Brain CancerK08NS090430 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI WOODWORTH, GRAEME F · 2014 to 2018
$748k
NCI NIH HHS P30 CA134274NCI NIH HHS T32 CA154274NINDS NIH HHS K08 NS090430NINDS NIH HHS K12 NS080223
6 · The paper itself

Abstract

Previously rodent preclinical research in gliomas frequently involved implantation of cell lines such as C6 and 9L into the rat brain. More recently, mouse models have taken over, the genetic manipulability of the mouse allowing the creation of genetically accurate models outweighed the disadvantage of its smaller brain size that limited time allowed for tumor progression. Here we illustrate a method that allows glioma formation in the rat using the replication competent avian-like sarcoma (RCAS) virus / tumor virus receptor-A (tv-a) transgenic system of post-natal cell type-specific gene transfer. The RCAS/tv-a model has emerged as a particularly versatile and accurate modeling technology by enabling spatial, temporal, and cell type-specific control of individual gene transformations and providing de novo formed glial tumors with distinct molecular subtypes mirroring human GBM. Nestin promoter-driven tv-a (Ntv-a) transgenic Sprague-Dawley rat founder lines were created and RCAS PDGFA and p53 shRNA constructs were used to initiate intracranial brain tumor formation. Tumor formation and progression were confirmed and visualized by magnetic resonance imaging (MRI) and spectroscopy. The tumors were analyzed using histopathological and immunofluorescent techniques. All experimental animals developed large, heterogeneous brain tumors that closely resembled human GBM. Median survival was 92 days from tumor initiation and 62 days from the first point of tumor visualization on MRI. Each tumor-bearing animal showed time dependent evidence of malignant progression to high-grade glioma by MRI and neurological examination. Post-mortem tumor analysis demonstrated the presence of several key characteristics of human GBM, including high levels of tumor cell proliferation, pseudopalisading necrosis, microvascular proliferation, invasion of tumor cells into surrounding tissues, peri-tumoral reactive astrogliosis, lymphocyte infiltration, presence of numerous tumor-associated microglia- and bone marrow-derived macrophages, and the formation of stem-like cell niches within the tumor. This transgenic rat model may enable detailed interspecies comparisons of fundamental cancer pathways and clinically relevant experimental imaging procedures and interventions that are limited by the smaller size of the mouse brain.

Indexed as

AnimalsAvian Sarcoma VirusesBrainCell Transformation, NeoplasticDisease Models, AnimalGenetic EngineeringGliomaHumansMacrophagesMagnetic Resonance ImagingMiceNestinPlatelet-Derived Growth FactorRatsRats, TransgenicTumor Suppressor Protein p53Nes protein, ratNestinPlatelet-Derived Growth Factorplatelet-derived growth factor ATumor Suppressor Protein p53

Identifiers

PMID28358926
PMCPMC5373526
OpenAlexW2599239082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.